Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and that can be difficult because UV-C is, in practical terms, an invisible tool.

Since the beginning of the pandemic, the world is acutely aware that infection control isn’t just for hospitals. Discussing these new use cases and how UV-C works, host Daniel Litwin spoke with Wendy Brady, Director of Global Marketing for Intellego Technologies.

“Pathogens are everywhere on the surfaces we touch and the air we breathe. UV-C can be an important tool to protect spaces outside of healthcare,” Brady said. But the key to successful UV-C disinfection is ensuring that you’ve delivered the right amount of ultraviolet irradiation to surfaces.

So, how exactly does UV-C light work?

“UV-C is part of the ultraviolet spectrum and it has a powerful germicidal effect on bacteria, viruses and fungi,” Brady explained. “The way it works is by breaking the DNA or RNA bonds in organisms so they can then no longer reproduce. It renders them inactive, but a sufficient amount of energy or irradiation must be delivered to surface in order to achieve a germicidal effect.”

With established and widespread use in hospitals, other industries are now looking to the technology to help combat pathogens and make public areas safer. Brady said that schools, airports, hotels, event venues, commercial office buildings and more are all beginning to employ different types of UV-C systems to provide a higher level of sanitization.

Because UV-C is often used in unoccupied spaces or in closed cabinet systems, it’s challenging for operators to know if their device is truly working and that all target areas have received enough irradiation to achieve sanitization. It’s not something they can see, but dosimeters provide that important piece of visible evidence.

UVC Dosimeters have a color-changing indicator area that shows the ‘dose’ or how much germicidal irradiation has been delivered. By seeing the dose, measured as 25, 50 or 100 mJ/cm², a person can verify that the device has delivered enough energy needed to kill SARS-CoV-2, MRSA or even C. Difficile,” Brady said.

With a dosimeter, users have accurate, visible confirmation and real-time evidence that a UV-C disinfection device has done its job. With this additional context, disinfecting can become a more efficient process and it builds confidence in the effectiveness of the technology.

“Dosimeters can also save time, as users can see when the disinfection cycle is successful. Operators are finding that some areas can be sanitized more quickly than expected because they can see when they’ve reached a target dose. This means they can use their UV-C equipment in a more efficient manner, sanitizing more areas and creating safer environments,” Brady added.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512